---
title: "Weekly Recap | Agilent Tech +6.49%, consensus target above spot"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299508156.md"
description: "Agilent Tech (A) advanced 6.49% this week to close at $156.47, beating the S&P 500 by roughly 6.57 percentage points. The stock opened Monday at $148, pulled back to $144.65, then climbed through the next four sessions to hit a week high of $156.89 on Thursday. Friday’s close of $156.47 came on volume of 4.85m shares, about twice the early-week pace. Daily volume averaged 35% above the 60-day median, pointing to active two-way trade during the rally."
datetime: "2026-09-19T05:26:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299508156.md)
  - [en](https://longbridge.com/en/news/299508156.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299508156.md)
generator: "portal-rs"
---

# Weekly Recap | Agilent Tech +6.49%, consensus target above spot

## The Week

Agilent Tech (A) advanced 6.49% this week to close at $156.47, beating the S&P 500 by roughly 6.57 percentage points. The stock opened Monday at $148, pulled back to $144.65, then climbed through the next four sessions to hit a week high of $156.89 on Thursday. Friday’s close of $156.47 came on volume of 4.85m shares, about twice the early-week pace. Daily volume averaged 35% above the 60-day median, pointing to active two-way trade during the rally.

## Key Events

The week’s news flow centred on dividends and a disclosed stake increase. On Monday, Corient Private Wealth LP reported boosting its position in Agilent. The company then announced quarterly cash dividends on Wednesday and Thursday at 25.5 cents and $0.26 per share, followed by a BRL 0.09 per-unit payout for Brazilian BDR holders on Friday. These moves fit with the roughly 0.65% dividend yield shown in the static data. The stock traded in line with Keysight and the broader sector on Friday.

## Analyst Ratings

Coverage stands at 23 firms: 12 rate it buy, 4 overweight and 7 hold, with no underweight or sell ratings. The consensus rating is buy, and the consensus target of $174.95 sits about 11.81% above the latest close. Targets range from $155 to $190, a spread that suggests real disagreement on valuation. Within the life-sciences tools and services peer group, Agilent ranks 4th out of 54 companies.

## The Week Ahead

No company-specific events are scheduled, so the calendar shifts to macro data. Tuesday brings the Richmond Fed composite index, Wednesday EIA crude and Cushing inventories, and Thursday jobless claims, current-account balance, new home sales and natural gas storage. Weaker macro prints could pressure sector sentiment; with the dividend now set, attention is likely to rotate toward liquidity and demand data.

## In Short

This week’s price strength came alongside a mostly buy-rated analyst base and an 11.81% gap to the consensus target, but the target range spans nearly $35, so the dispersion remains wide. Valuation is mid-to-high: P/E around 30.6x and P/B about 5.99x. The latest session’s money flow showed large and medium orders as net buyers while small orders turned net sellers, a split in conviction. The question ahead is whether macro data can sustain the move or whether the volume pickup resolves into a pullback from the highs.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [A.US](https://longbridge.com/en/quote/A.US.md)

## Related News & Research

- [Agilent to buy pathology software maker Proscia for $240 million](https://longbridge.com/en/news/301707898.md)
- [Why Agilent Is Spending up to $270 Million on an AI Pathology Specialist](https://longbridge.com/en/news/301850952.md)
- [How New Lab Automation Tools At Agilent Technologies (A) Have Changed Its Investment Story](https://longbridge.com/en/news/300886709.md)
- [Is Agilent Technologies (A) Trading At A Premium After New Launches?](https://longbridge.com/en/news/300832557.md)
- [ANALYSIS-Market selloff, rising rates test AI data centre deal boom](https://longbridge.com/en/news/301979561.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**